This company listing is no longer active
Resumen de acción NMTR
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 3 riesgos adicionales
Competidores de 9 Meters Biopharma, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$6.56 |
| 52 Week Low | US$0.18 |
| Beta | 1.48 |
| 1 Month Change | -72.75% |
| 3 Month Change | -85.45% |
| 1 Year Change | -96.00% |
| 3 Year Change | -98.32% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.83% |
Noticias y actualizaciones recientes
Recent updates
9 Meters Biopharma to execute 1-for-20 reverse stock split
Oct 179 Meters Biopharma GAAP EPS of -$0.04 in-line
Aug 159 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome
Jun 149 Meters drug effective in treating rare COVID-19 complication in children
May 269 Meters Bio gains 5% on Adage Capital stake disclosure
Dec 299 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications
Dec 219 Meters Bio launches equity offering
Dec 11Rentabilidad de los accionistas
| NMTR | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -71.1% | 1.1% | 0.7% |
| 1Y | -96.0% | 9.5% | 23.9% |
Rentabilidad vs. Industria: NMTR underperformed the US Pharmaceuticals industry which returned -1.3% over the past year.
Rentabilidad vs. Mercado: NMTR underperformed the US Market which returned 16.1% over the past year.
Volatilidad de los precios
| NMTR volatility | |
|---|---|
| NMTR Average Weekly Movement | 22.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: NMTR's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: NMTR's weekly volatility has increased from 17% to 22% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 10 | Bethany Sensenig | www.9meters.com |
Resumen de fundamentos de 9 Meters Biopharma, Inc.
| Estadísticas fundamentales de NMTR | |
|---|---|
| Capitalización bursátil | US$2.82m |
| Beneficios(TTM) | -US$46.28m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.1x
Ratio precio-beneficio (PE)¿Está NMTR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NMTR | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$46.28m |
| Beneficios | -US$46.28m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -3.20 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | -80.5% |
¿Cómo se ha desempeñado NMTR a largo plazo?
Ver rendimiento histórico y comparativa